Dr. Peter Neubeck

Principal

Dr. Peter Neubeck joined the Life Science practice in 2008 as Senior Associate, based in Munich. He is a Principal at TVM Capital in Munich and as such involved in deal origination and the evaluation of new investments, as well as research and support for existing portfolio companies with an emphasis on clinical development stage to commercial stage investments, including virtual asset development type investments (‘Project-Focused-Companies’)

Prior to joining TVM Capital, he worked at Novartis Pharma as Global Project Leader for the Cardiovascular & Metabolism Business Franchise, and was responsible for the life cycle strategy and development of the novel potential blockbuster antihypertensive Rasilez®/Tekturna® , including the recent FDA approval of the first fixed dose combination Tekturna HCT®. Prior to this role he worked as manager in the Pharma Strategic Planning Group focusing on the global disease area strategy of Novartis.

He has completed his medical studies at Ludwig-Maximilians-University München and Harvard Medical School and holds a doctoral degree for his work in non-invasive cardiovascular imaging using electron beam tomography. After pursuing postgraduate training in neurology and internal medicine in Munich, the Cleveland Clinic and Beth Israel Deaconess Medical Center, he obtained an MBA at INSEAD and worked at McKinsey & Company’s Zurich office, serving several of the top pharmaceutical companies in turnaround and growth projects.